A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS
OBJECTIVE: Capecitabine is an oral 5-fluorouracil (5-FU) pro-drug commonly used to treat colorectal carcinoma and other tumours. About 35% of patients experience dose-limiting toxicity. The few proven genetic biomarkers of 5-FU toxicity are rare variants and polymorphisms, respectively, at candidate...
Saved in:
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Text |
Language: | English |
Published: |
BMJ Publishing Group
2015
|
Subjects: | |
Online Access: | https://pmc.ncbi.nlm.nih.gov/articles/PMC4283622/ https://pubmed.ncbi.nlm.nih.gov/24647007 http://dx.doi.org/10.1136/gutjnl-2013-306571 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|